2018 Acute Heart Failure Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Acute Heart Failure Market
2018 Acute Heart Failure Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Acute Heart Failure Market is a comprehensive report on Acute Heart Failure pipeline.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Acute Heart Failure pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Acute Heart Failure pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Acute Heart Failure pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Acute Heart Failure pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Acute Heart Failure pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Acute Heart Failure pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 ACUTE HEART FAILURE PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Acute Heart Failure Pipeline Snapshot
2.3 Acute Heart Failure Pipeline by Phase
2.4 Acute Heart Failure Pipeline by Company
2.5 Acute Heart Failure Pipeline by Mechanism of Action
3 ACUTE HEART FAILURE- COMPANY WISE PIPELINE ANALYSIS
AETAS Pharma Co.,Ltd.
Amgen Inc.
Bristol-Myers Squibb
Capella Biosciences
Capricor Therapeutics, Inc.
Cardiorentis AG
Lee's Pharmaceutical Holdings Limited
Novartis AG
Ono Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Renova Therapeutics, Inc.
Theravance Biopharma Inc
Trevena, Inc.
4 ACUTE HEART FAILURE R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ACUTE HEART FAILURE PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 ACUTE HEART FAILURE PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Acute Heart Failure Pipeline Snapshot
2.3 Acute Heart Failure Pipeline by Phase
2.4 Acute Heart Failure Pipeline by Company
2.5 Acute Heart Failure Pipeline by Mechanism of Action
3 ACUTE HEART FAILURE- COMPANY WISE PIPELINE ANALYSIS
AETAS Pharma Co.,Ltd.
Amgen Inc.
Bristol-Myers Squibb
Capella Biosciences
Capricor Therapeutics, Inc.
Cardiorentis AG
Lee's Pharmaceutical Holdings Limited
Novartis AG
Ono Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Renova Therapeutics, Inc.
Theravance Biopharma Inc
Trevena, Inc.
4 ACUTE HEART FAILURE R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ACUTE HEART FAILURE PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Acute Heart Failure Pipeline by Phase, H2- 2018
Figure 2: Acute Heart Failure Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Acute Heart Failure Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Acute Heart Failure Pipeline by Phase, H2- 2018
Figure 2: Acute Heart Failure Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Acute Heart Failure Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Acute Heart Failure Pipeline by Phase, H2- 2018
Acute Heart Failure Pipeline by Companies, H2- 2018
Acute Heart Failure Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 2: Amgen Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 3: Bristol-Myers Squibb Acute Heart Failure Pipeline Drugs, H2- 2018
Table 4: Capella Biosciences Acute Heart Failure Pipeline Drugs, H2- 2018
Table 5: Capricor Therapeutics, Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 6: Cardiorentis AG Acute Heart Failure Pipeline Drugs, H2- 2018
Table 7: Lee's Pharmaceutical Holdings Limited Acute Heart Failure Pipeline Drugs, H2- 2018
Table 8: Novartis AG Acute Heart Failure Pipeline Drugs, H2- 2018
Table 9: Ono Pharmaceutical Co., Ltd. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 10: PhaseBio Pharmaceuticals, Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 11: Renova Therapeutics, Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 12: Theravance Biopharma Inc Acute Heart Failure Pipeline Drugs, H2- 2018
Table 13: Trevena, Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Acute Heart Failure Pipeline by Phase, H2- 2018
Acute Heart Failure Pipeline by Companies, H2- 2018
Acute Heart Failure Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 2: Amgen Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 3: Bristol-Myers Squibb Acute Heart Failure Pipeline Drugs, H2- 2018
Table 4: Capella Biosciences Acute Heart Failure Pipeline Drugs, H2- 2018
Table 5: Capricor Therapeutics, Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 6: Cardiorentis AG Acute Heart Failure Pipeline Drugs, H2- 2018
Table 7: Lee's Pharmaceutical Holdings Limited Acute Heart Failure Pipeline Drugs, H2- 2018
Table 8: Novartis AG Acute Heart Failure Pipeline Drugs, H2- 2018
Table 9: Ono Pharmaceutical Co., Ltd. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 10: PhaseBio Pharmaceuticals, Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 11: Renova Therapeutics, Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
Table 12: Theravance Biopharma Inc Acute Heart Failure Pipeline Drugs, H2- 2018
Table 13: Trevena, Inc. Acute Heart Failure Pipeline Drugs, H2- 2018
